BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ferrari SM, Elia G, Ragusa F, Ruffilli I, La Motta C, Paparo SR, Patrizio A, Vita R, Benvenga S, Materazzi G, Fallahi P, Antonelli A. Novel treatments for anaplastic thyroid carcinoma. Gland Surg 2020;9:S28-42. [PMID: 32055496 DOI: 10.21037/gs.2019.10.18] [Cited by in Crossref: 33] [Cited by in F6Publishing: 39] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu AC, Han AY, Cronkite DA, Sajed D, St John MA. Anaplastic Transformation of Differentiated Thyroid Carcinoma. Laryngoscope 2023;133:437-42. [PMID: 35779253 DOI: 10.1002/lary.30277] [Reference Citation Analysis]
2 Gao H, Wang W, Li Q. GANT61 suppresses cell survival, invasion and epithelial-mesenchymal transition through inactivating AKT/mTOR and JAK/STAT3 pathways in anaplastic thyroid carcinoma. Cancer Biol Ther 2022;23:369-77. [PMID: 35491899 DOI: 10.1080/15384047.2022.2051158] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
3 Yuan J, Guo Y. Targeted Therapy for Anaplastic Thyroid Carcinoma: Advances and Management. Cancers (Basel) 2022;15. [PMID: 36612173 DOI: 10.3390/cancers15010179] [Reference Citation Analysis]
4 Elia G, Patrizio A, Ragusa F, Paparo SR, Mazzi V, Balestri E, Botrini C, Rugani L, Benvenga S, Materazzi G, Spinelli C, Antonelli A, Fallahi P, Ferrari SM. Molecular features of aggressive thyroid cancer. Front Oncol 2022;12:1099280. [PMID: 36605433 DOI: 10.3389/fonc.2022.1099280] [Reference Citation Analysis]
5 Yang S, Ji D, Xue F, Chen T, Wang Y, Ji Q. Neoadjuvant famitinib and camrelizumab, a new combined therapy allowing surgical resection of the primary site for anaplastic thyroid carcinoma. Cancer Rep (Hoboken) 2023;6:e1770. [PMID: 36535914 DOI: 10.1002/cnr2.1770] [Reference Citation Analysis]
6 Heidari A, Iorgulescu S, Robinson O, Hu L, Vauclin C, Schiltz N, Sondermann S, Maclennan L, Smith J, Williamson L, Heidari A, Iorgulescu S, Robinson O, Hu L, Vauclin C, Ntalie Schiltz N, Sondermann S, Maclennan L, Smith J, Williamson L, Heidari A, Iorgulescu S, Robinson O, Williamson L, Hu L, Vauclin C, Schiltz N, Sondermann S, Maclennan L, Smith J, Heidari A, Torfeh Z. CERN Large Hadron Collider (LHC) Radiation Source for Magnetic Resonance Biospectroscopy in Metabolic and Molecular Imaging and Diagnosis of Cancer. JNDC 2022;3:29-30. [DOI: 10.14302/issn.2377-2549.jndc-22-4351] [Reference Citation Analysis]
7 Marotta V, Cennamo M, La Civita E, Vitale M, Terracciano D. Cell-Free DNA Analysis within the Challenges of Thyroid Cancer Management. Cancers 2022;14:5370. [DOI: 10.3390/cancers14215370] [Reference Citation Analysis]
8 Pan Z, Xu T, Bao L, Hu X, Jin T, Chen J, Chen J, Qian Y, Lu X, Li L, Zheng G, Zhang Y, Zou X, Song F, Zheng C, Jiang L, Wang J, Tan Z, Huang P, Ge M. CREB3L1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by remodeling the tumor microenvironment. Mol Cancer 2022;21:190. [PMID: 36192735 DOI: 10.1186/s12943-022-01658-x] [Reference Citation Analysis]
9 Puliafito I, Esposito F, Prestifilippo A, Marchisotta S, Sciacca D, Vitale MP, Giuffrida D. Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects. Front Endocrinol 2022;13:860671. [DOI: 10.3389/fendo.2022.860671] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Gong Y, Xu F, Deng L, Peng L, Teekaraman Y. Recognition of Key Genes in Human Anaplastic Thyroid Cancer via the Weighing Gene Coexpression Network. BioMed Research International 2022;2022:1-17. [DOI: 10.1155/2022/2244228] [Reference Citation Analysis]
11 Zhou Y, Zhao Y, Ding X, Liang J, Xu H, Lin Y, Khan HH, Shi B. A New Way Out of the Predicament of Anaplastic Thyroid Carcinoma From Existing Data Analysis. Front Endocrinol 2022;13:887906. [DOI: 10.3389/fendo.2022.887906] [Reference Citation Analysis]
12 Birden N, Selvi Gunel N, Ozates NP, Goker Bagca B, Gunduz C, Sabour Takanlou L, Sabour Takanlou M, Biray Avci C. The effects of Epigallocatechin-3-gallate and Dabrafenib combination on apoptosis and the genes involved in epigenetic events in anaplastic thyroid cancer cells. Med Oncol 2022;39. [DOI: 10.1007/s12032-022-01688-x] [Reference Citation Analysis]
13 Ragusa F, Ferrari SM, Elia G, Paparo SR, Balestri E, Botrini C, Patrizio A, Mazzi V, Guglielmi G, Foddis R, Spinelli C, Ulisse S, Antonelli A, Fallahi P. Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. Int J Mol Sci 2022;23:5731. [PMID: 35628540 DOI: 10.3390/ijms23105731] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Luo Y, Yang Y, Shen C, Ma B, Xu W, Wang Q, Zhang Y, Liao T, Wei W, Wang Y. Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma. Front Endocrinol 2022;13:859013. [DOI: 10.3389/fendo.2022.859013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 La Marca JE, Ely RW, Diepstraten ST, Burke P, Kelly GL, Humbert PO, Richardson HE. A Drosophila in vivo chemical screen reveals that combination drug treatment targeting MEK and DGKα mitigates Ras-driven polarity-impaired tumourigenesis.. [DOI: 10.1101/2022.03.14.484232] [Reference Citation Analysis]
16 Dabravolski SA, Nikiforov NG, Zhuravlev AD, Orekhov NA, Mikhaleva LM, Orekhov AN. The Role of Altered Mitochondrial Metabolism in Thyroid Cancer Development and Mitochondria-Targeted Thyroid Cancer Treatment. Int J Mol Sci 2021;23:460. [PMID: 35008887 DOI: 10.3390/ijms23010460] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
17 Luongo C, Porcelli T, Sessa F, De Stefano MA, Scavuzzo F, Damiano V, Klain M, Bellevicine C, Matano E, Troncone G, Schlumberger M, Salvatore D. Combination of Lenvatinib and Pembrolizumab as Salvage Treatment for Paucicellular Variant of Anaplastic Thyroid Cancer: A Case Report. Curr Oncol 2021;28:5401-7. [PMID: 34940089 DOI: 10.3390/curroncol28060450] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Chien CC, Wu MS, Chou SW, Jargalsaikhan G, Chen YC. Roles of reactive oxygen species, mitochondrial membrane potential, and p53 in evodiamine-induced apoptosis and G2/M arrest of human anaplastic thyroid carcinoma cells. Chin Med 2021;16:134. [PMID: 34886886 DOI: 10.1186/s13020-021-00505-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
19 Lee WK, Cheng SY. Targeting transcriptional regulators for treatment of anaplastic thyroid cancer. J Cancer Metastasis Treat 2021;7:27. [PMID: 34761120 DOI: 10.20517/2394-4722.2021.58] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Tarabichi M, Demetter P, Craciun L, Maenhaut C, Detours V. Thyroid cancer under the scope of emerging technologies. Mol Cell Endocrinol 2021;541:111491. [PMID: 34740746 DOI: 10.1016/j.mce.2021.111491] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
21 Chi T, Wang M, Wang X, Yang K, Xie F, Liao Z, Wei P. PPAR-γ Modulators as Current and Potential Cancer Treatments. Front Oncol 2021;11:737776. [PMID: 34631571 DOI: 10.3389/fonc.2021.737776] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
22 Adam P, Kircher S, Sbiera I, Koehler VF, Berg E, Knösel T, Sandner B, Fenske WK, Bläker H, Smaxwil C, Zielke A, Sipos B, Allelein S, Schott M, Dierks C, Spitzweg C, Fassnacht M, Kroiss M. FGF-Receptors and PD-L1 in Anaplastic and Poorly Differentiated Thyroid Cancer: Evaluation of the Preclinical Rationale. Front Endocrinol (Lausanne) 2021;12:712107. [PMID: 34475850 DOI: 10.3389/fendo.2021.712107] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
23 Ferrari SM, Elia G, Ragusa F, Paparo SR, Mazzi V, Miccoli M, Galdiero MR, Varricchi G, Foddis R, Guglielmi G, Spinelli C, La Motta C, Benvenga S, Antonelli A, Fallahi P. Lenvatinib: an investigational agent for the treatment of differentiated thyroid cancer. Expert Opin Investig Drugs 2021;30:913-21. [PMID: 34428101 DOI: 10.1080/13543784.2021.1972971] [Reference Citation Analysis]
24 Schmidt C, Babu T, Kostrhunova H, Timm A, Basu U, Ott I, Gandin V, Brabec V, Gibson D. Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs? J Med Chem 2021;64:11364-78. [PMID: 34342437 DOI: 10.1021/acs.jmedchem.1c00706] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
25 Anschlag A, Greene BH, KÖnneker L, Luster M, Nagarajah J, WÄchter S, Wunderlich A, Pfestroff A. Effect of Kinase Inhibitors on the Technetium-99m Uptake into Thyroid Carcinoma Cells In Vitro. In Vivo 2021;35:721-9. [PMID: 33622865 DOI: 10.21873/invivo.12313] [Reference Citation Analysis]
26 Ge MH, Zhu XH, Shao YM, Wang C, Huang P, Wang Y, Jiang Y, Maimaitiyiming Y, Chen E, Yang C, Naranmandura H. Synthesis and characterization of CD133 targeted aptamer-drug conjugates for precision therapy of anaplastic thyroid cancer. Biomater Sci 2021;9:1313-24. [PMID: 33350399 DOI: 10.1039/d0bm01832e] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
27 Lin R, Ma B, Liu N, Zhang L, He T, Liu X, Chen T, Liu W, Liang Y, Wang T, Ni G, Liu X, Yang N, Zhang J, Yuan J. Targeted radioimmunotherapy with the iodine-131-labeled caerin 1.1 peptide for human anaplastic thyroid cancer in nude mice. Ann Nucl Med 2021;35:811-22. [PMID: 33948902 DOI: 10.1007/s12149-021-01618-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
28 Amaral M, Charmier AJ, Afonso RA, Catarino J, Faísca P, Carvalho L, Ascensão L, Coelho JMP, Gaspar MM, Reis CP. Gold-Based Nanoplataform for the Treatment of Anaplastic Thyroid Carcinoma: A Step Forward. Cancers (Basel) 2021;13:1242. [PMID: 33808984 DOI: 10.3390/cancers13061242] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
29 Gild ML, Tsang VHM, Clifton-Bligh RJ, Robinson BG. Multikinase inhibitors in thyroid cancer: timing of targeted therapy. Nat Rev Endocrinol 2021;17:225-34. [PMID: 33603220 DOI: 10.1038/s41574-020-00465-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 7.5] [Reference Citation Analysis]
30 Xiong L, Lin XM, Nie JH, Ye HS, Liu J. Resveratrol and its Nanoparticle suppress Doxorubicin/Docetaxel-resistant anaplastic Thyroid Cancer Cells in vitro and in vivo. Nanotheranostics 2021;5:143-54. [PMID: 33457193 DOI: 10.7150/ntno.53844] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
31 Barbaro D, Lapi P, Viacava P, Torregrossa L. Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe. BMJ Case Rep 2020;13:e236934. [PMID: 33370973 DOI: 10.1136/bcr-2020-236934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Diethelm-Varela B. Using NMR Spectroscopy in the Fragment-Based Drug Discovery of Small-Molecule Anticancer Targeted Therapies. ChemMedChem 2021;16:725-42. [PMID: 33236493 DOI: 10.1002/cmdc.202000756] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
33 Seok JY, Astvatsaturyan K, Peralta-Venturina M, Lai J, Fan X. TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma. Int J Surg Pathol 2021;29:368-77. [PMID: 33289434 DOI: 10.1177/1066896920978597] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
34 Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S, Antonelli A. Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Semin Cancer Biol 2020:S1044-579X(20)30249-2. [PMID: 33249201 DOI: 10.1016/j.semcancer.2020.11.013] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 7.7] [Reference Citation Analysis]
35 Su X, Liu J, Zhang H, Gu Q, Zhou X, Ji M, Yao D. Lenvatinib Promotes the Antitumor Effect of Doxorubicin in Anaplastic Thyroid Cancer. Onco Targets Ther 2020;13:11183-92. [PMID: 33173310 DOI: 10.2147/OTT.S278349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
36 Song T, Chen L, Zhang H, Lu Y, Yu K, Zhan W, Fang M. Multimodal treatment based on thyroidectomy improves survival in patients with metastatic anaplastic thyroid carcinoma: a SEER analysis from 1998 to 2015. Gland Surg 2020;9:1205-13. [PMID: 33224795 DOI: 10.21037/gs-20-503] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
37 Liao Y, Gao Y, Chang A, Li Z, Wang H, Cao J, Gu W, Tang R. Melatonin synergizes BRAF-targeting agent dabrafenib for the treatment of anaplastic thyroid cancer by inhibiting AKT/hTERT signalling. J Cell Mol Med 2020;24:12119-30. [PMID: 32935463 DOI: 10.1111/jcmm.15854] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
38 Guo WP, Tang D, Pang YY, Li XJ, Chen G, Huang ZG, Tang XZ, Lai QQ, Gan JY, Huang XL, Liu XF, Wei ZX, Ma W. Immunohistochemical basigin expression level in thyroid cancer tissues. World J Surg Oncol 2020;18:240. [PMID: 32891152 DOI: 10.1186/s12957-020-01975-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
39 Fallahi P, Ferrari SM, Elia G, Ragusa F, Patrizio A, Paparo SR, Marone G, Galdiero MR, Guglielmi G, Foddis R, Cristaudo A, Antonelli A. Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin. Semin Cancer Biol 2020:S1044-579X(20)30149-8. [PMID: 32569821 DOI: 10.1016/j.semcancer.2020.06.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]